Scott W. Hiebert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Scott W. Hiebert has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Kristy R. Stengel
Albert Einstein College of Medicine 1 Department of Cell Biology Bronx, New York
21 shared publications - Christopher S. Williams
Department of Medicine, Division of Gastroenterology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
9 shared publications - Srividya Bhaskara
Asst. Professor, Department Of MCA, Sree Vidyanikethan Institute Of Management, Tirupati, India
8 shared publications Pankaj Acharya
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN
7 shared publicationsQi Liu
Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA
7 shared publicationsYue Zhao
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
7 shared publications
Latest Publications
- 17 June 2026
- Published by Elsevier in Molecular Cell
Mtg16/Eto2 tumor suppressor maintains and establishes repression by distinct mechanisms
- 17 June 2026
- Published by Elsevier in Molecular Cell
Mtg16/Eto2 tumor suppressor maintains and establishes repression by distinct mechanisms
- 1 May 2025
- Published by Elsevier in Experimental Hematology
- Vol. 147, 104793
Mtg16 NHR1 mutations cause defects in lymphopoiesis and the response to anemia
- 1 May 2025
- Published by Elsevier in Experimental Hematology
- Vol. 147, 104793
Mtg16 NHR1 mutations cause defects in lymphopoiesis and the response to anemia
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 14
eNRSA: a faster and more powerful approach for nascent transcriptome analysis
Nascent RNA sequencing tracks primary transcriptional events, making it crucial for studying the immediate regulatory changes of genes and enhancers in response to both endogenous and exogenous stimuli. NRSA is a widely used tool for analyzing nascent transcriptomic data, enabling quantification of transcriptional changes at proximal promoters and gene bodies, estimation of pausing indices, identifying active enhancers, and establishing enhancer–target gene relationships. To improve its functionality and broaden its applicability to diverse organisms and complex study designs, we have developed an enhanced version, eNRSA. Key advancements include adaptive selection of major transcripts, support for any organism with known gene structures, compatibility with complex study designs, and identification of alternative transcription start and termination sites, as well as transcription readthrough events. Additionally, eNRSA achieves a ∼20-fold increase in analysis speed while significantly reducing memory usage. These enhancements make eNRSA a faster, more versatile, and more powerful tool for nascent transcriptome analysis. eNRSA is freely available at https://bioinfo.vanderbilt.edu/eNRSA/.
- 6 January 2025
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 14
Open AccesseNRSA: a faster and more powerful approach for nascent transcriptome analysis
Nascent RNA sequencing tracks primary transcriptional events, making it crucial for studying the immediate regulatory changes of genes and enhancers in response to both endogenous and exogenous stimuli. NRSA is a widely used tool for analyzing nascent transcriptomic data, enabling quantification of transcriptional changes at proximal promoters and gene bodies, estimation of pausing indices, identifying active enhancers, and establishing enhancer–target gene relationships. To improve its functionality and broaden its applicability to diverse organisms and complex study designs, we have developed an enhanced version, eNRSA. Key advancements include adaptive selection of major transcripts, support for any organism with known gene structures, compatibility with complex study designs, and identification of alternative transcription start and termination sites, as well as transcription readthrough events. Additionally, eNRSA achieves a ∼20-fold increase in analysis speed while significantly reducing memory usage. These enhancements make eNRSA a faster, more versatile, and more powerful tool for nascent transcriptome analysis. eNRSA is freely available at https://bioinfo.vanderbilt.edu/eNRSA/.
- Open Access
- 10 April 2024
- Published by Elsevier in Cell Genomics
- Vol. 4 (4) , 100537
Mutant FOXO1 controls an oncogenic network via enhancer accessibility
- 10 April 2024
- Published by Elsevier in Cell Genomics
- Vol. 4 (4) , 100537
Open AccessMutant FOXO1 controls an oncogenic network via enhancer accessibility
- 16 September 2023
- Published by Elsevier in Trends in Cancer
- Vol. 10 (1) , 65-75
Chemical-genetics refines transcription factor regulatory circuits
- 16 September 2023
- Published by Elsevier in Trends in Cancer
- Vol. 10 (1) , 65-75
Chemical-genetics refines transcription factor regulatory circuits
- Open Access
- 30 June 2023
- Published by Springer Nature in Research Square
A dual indexed approach to small RNA sequencing library preparation for PRO-seq
Advances in next generation sequencing (NGS) technologies have vastly increased the number of samples that can be sequenced together and reduced the cost per sample. To fully utilize the increased capacity of standard sequencers, samples must be multiplexed. Sample multiplexing allows libraries to be pooled and sequenced together on a single sequencing run. Multiplexing requires libraries that have been prepared with a unique 6-12 bp sequence (index). The most efficient and cost-effective sequencing platforms rely on paired end sequencing methodologies to improve multiplexing efficiency. While libraries with a single index can be sequenced on paired end sequencers they reduce the efficiency of demultiplexing and increase the sequencing cost due to index mis-assignment. However, some specialized library preparation protocols, like the TruSeq Small RNA protocol, that rely on custom sequencing adapters have not been updated by Illumnia to include a second index. Commercially available kits for creating small RNA paired end libraries are expensive and do not provide the level of transparency required to adapt the kits to custom protocols. Here, we provide a dual-indexed approach to small RNA library preparatio that reduces the cost per library by nearly half (compared to the NEXTFLEX v3 kit) and includes all sequences for the oligonucleotides required. While this workflow was developed for PRO-seq libraries, deviations from the original TruSeq Small RNA library preparation protocol are denoted and alternate reagents are provided to facilitate adaptation of existing protocols.
- 30 June 2023
- Published by Springer Nature in Research Square
Open AccessA dual indexed approach to small RNA sequencing library preparation for PRO-seq
Advances in next generation sequencing (NGS) technologies have vastly increased the number of samples that can be sequenced together and reduced the cost per sample. To fully utilize the increased capacity of standard sequencers, samples must be multiplexed. Sample multiplexing allows libraries to be pooled and sequenced together on a single sequencing run. Multiplexing requires libraries that have been prepared with a unique 6-12 bp sequence (index). The most efficient and cost-effective sequencing platforms rely on paired end sequencing methodologies to improve multiplexing efficiency. While libraries with a single index can be sequenced on paired end sequencers they reduce the efficiency of demultiplexing and increase the sequencing cost due to index mis-assignment. However, some specialized library preparation protocols, like the TruSeq Small RNA protocol, that rely on custom sequencing adapters have not been updated by Illumnia to include a second index. Commercially available kits for creating small RNA paired end libraries are expensive and do not provide the level of transparency required to adapt the kits to custom protocols. Here, we provide a dual-indexed approach to small RNA library preparatio that reduces the cost per library by nearly half (compared to the NEXTFLEX v3 kit) and includes all sequences for the oligonucleotides required. While this workflow was developed for PRO-seq libraries, deviations from the original TruSeq Small RNA library preparation protocol are denoted and alternate reagents are provided to facilitate adaptation of existing protocols.
- 10 January 2023
- Published by Elsevier in Molecular Cell
- Vol. 83 (4) , 507-522.e6
Human SMARCA5 is continuously required to maintain nucleosome spacing
- 10 January 2023
- Published by Elsevier in Molecular Cell
- Vol. 83 (4) , 507-522.e6
Human SMARCA5 is continuously required to maintain nucleosome spacing
- 16 November 2022
- Published by Elsevier in Molecular Cell
- Vol. 82 (23) , 4428-4442.e7
PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets
- 16 November 2022
- Published by Elsevier in Molecular Cell
- Vol. 82 (23) , 4428-4442.e7
PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2362
Abstract 2362: Pax3-foxo1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets
Background: Gene expression networks are perturbed in every human malignancy. One common way that this occurs is through chromosomal translocations such as the the t(2;13)(q35;q14), which creates the oncogenic transcription factor, PAX3-FOXO1, in alveolar rhabdomyosarcoma (aRMS). Identification of the direct transcriptional targets and mechanisms of control by translocated transcription factors is critical to our understanding of disease etiology and the development of targeted therapeutic approaches. However, defining the genes directly controlled by DNA binding proteins and the mechanisms of regulation at those direct target genes is challenging, because traditional genetic approaches to inactivate transcription factors cannot distinguish direct from indirect changes in gene expression. Methods: A CRISPR-based approach was used to engineer the endogenous PAX3-FOXO1 locus to incorporate the FKBP12F36V degron tag. This allowed degradation of PAX3-FOXO1 within 2 hr of treatment with the proteolysis targeting chimera, dTAG-47. We performed short time courses to analyze nascent transcription (precision nuclear run-on sequencing; PRO-seq), chromatin accessibility (ATAC-seq), and genome-wide mapping of transcriptional complexes (CUT&RUN). This identified a small cohort of high-confidence PAX3-FOXO1 gene targets and associated PAX3-FOXO1-regulated enhancer elements. In addition, we used CRISPR editing to add APEX2 and 3XFLAG tags to PAX3-FOXO1 to enable deep proteomics to identify PAX3-FOXO1-associated transcriptional complexes in aRMS cell lines. Results: Degradation of PAX3-FOXO1-FKBP12F36V led to growth inhibition, hallmarks of myogenic differentiation, and reduced growth in soft agar. PAX3-FOXO1 binding was detected at over 44,000 sites throughout the genome using CUT&RUN, and loss of chromatin bound PAX3-FOXO1 was observed within 2-4hr of PAX3-FOXO1 degradation. PRO-seq analysis defined a core transcriptional network that rapidly collapsed upon PAX3-FOXO1 degradation. Unexpectedly, loss of PAX3-FOXO1 impaired RNA polymerase pause release and transcription elongation at regulated gene targets. Deep proteomic analysis showed that PAX3-FOXO1 was in close proximity to many transcriptional regulatory complexes, but appeared to coordinate the activity of these complexes at only a few hundred sites. Moreover, the continued presence of PAX3-FOXO1 at these elements was required to maintain chromatin accessibility. Conclusion: This work demonstrates the utility of using rapid degradation of endogenous transcription factors to define their direct transcription targets and the mechanisms by which these factors control gene expression. Overall, this work provides a detailed mechanism by which PAX3-FOXO1 maintains an oncogenic transcriptional regulatory network, and emphasizes the utility of PAX3-FOXO1 as a therapeutic target in aRMS. Citation Format: Susu Zhang, Jing Wang, Qi Liu, Hayes McDonald, Monica Bomber, Hillary Layden, Jacob Ellis, Scott Borinstein, Scott Hiebert, Kristy Stengel. Pax3-foxo1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2362.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2362
Open AccessAbstract 2362: Pax3-foxo1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets
Background: Gene expression networks are perturbed in every human malignancy. One common way that this occurs is through chromosomal translocations such as the the t(2;13)(q35;q14), which creates the oncogenic transcription factor, PAX3-FOXO1, in alveolar rhabdomyosarcoma (aRMS). Identification of the direct transcriptional targets and mechanisms of control by translocated transcription factors is critical to our understanding of disease etiology and the development of targeted therapeutic approaches. However, defining the genes directly controlled by DNA binding proteins and the mechanisms of regulation at those direct target genes is challenging, because traditional genetic approaches to inactivate transcription factors cannot distinguish direct from indirect changes in gene expression. Methods: A CRISPR-based approach was used to engineer the endogenous PAX3-FOXO1 locus to incorporate the FKBP12F36V degron tag. This allowed degradation of PAX3-FOXO1 within 2 hr of treatment with the proteolysis targeting chimera, dTAG-47. We performed short time courses to analyze nascent transcription (precision nuclear run-on sequencing; PRO-seq), chromatin accessibility (ATAC-seq), and genome-wide mapping of transcriptional complexes (CUT&RUN). This identified a small cohort of high-confidence PAX3-FOXO1 gene targets and associated PAX3-FOXO1-regulated enhancer elements. In addition, we used CRISPR editing to add APEX2 and 3XFLAG tags to PAX3-FOXO1 to enable deep proteomics to identify PAX3-FOXO1-associated transcriptional complexes in aRMS cell lines. Results: Degradation of PAX3-FOXO1-FKBP12F36V led to growth inhibition, hallmarks of myogenic differentiation, and reduced growth in soft agar. PAX3-FOXO1 binding was detected at over 44,000 sites throughout the genome using CUT&RUN, and loss of chromatin bound PAX3-FOXO1 was observed within 2-4hr of PAX3-FOXO1 degradation. PRO-seq analysis defined a core transcriptional network that rapidly collapsed upon PAX3-FOXO1 degradation. Unexpectedly, loss of PAX3-FOXO1 impaired RNA polymerase pause release and transcription elongation at regulated gene targets. Deep proteomic analysis showed that PAX3-FOXO1 was in close proximity to many transcriptional regulatory complexes, but appeared to coordinate the activity of these complexes at only a few hundred sites. Moreover, the continued presence of PAX3-FOXO1 at these elements was required to maintain chromatin accessibility. Conclusion: This work demonstrates the utility of using rapid degradation of endogenous transcription factors to define their direct transcription targets and the mechanisms by which these factors control gene expression. Overall, this work provides a detailed mechanism by which PAX3-FOXO1 maintains an oncogenic transcriptional regulatory network, and emphasizes the utility of PAX3-FOXO1 as a therapeutic target in aRMS. Citation Format: Susu Zhang, Jing Wang, Qi Liu, Hayes McDonald, Monica Bomber, Hillary Layden, Jacob Ellis, Scott Borinstein, Scott Hiebert, Kristy Stengel. Pax3-foxo1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2362.
- Open Access
- 23 May 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (10)
MTG16 regulates colonic epithelial differentiation, colitis, and tumorigenesis by repressing E protein transcription factors
Aberrant epithelial differentiation and regeneration contribute to colon pathologies, including inflammatory bowel disease (IBD) and colitis-associated cancer (CAC). Myeloid translocation gene 16 (MTG16, also known as CBFA2T3) is a transcriptional corepressor expressed in the colonic epithelium. MTG16 deficiency in mice exacerbates colitis and increases tumor burden in CAC, though the underlying mechanisms remain unclear. Here, we identified MTG16 as a central mediator of epithelial differentiation, promoting goblet and restraining enteroendocrine cell development in homeostasis and enabling regeneration following dextran sulfate sodium–induced (DSS-induced) colitis. Transcriptomic analyses implicated increased Ephrussi box–binding transcription factor (E protein) activity in MTG16-deficient colon crypts. Using a mouse model with a point mutation that attenuates MTG16:E protein interactions ( Mtg16 P209T ), we showed that MTG16 exerts control over colonic epithelial differentiation and regeneration by repressing E protein–mediated transcription. Mimicking murine colitis, MTG16 expression was increased in biopsies from patients with active IBD compared with unaffected controls. Finally, uncoupling MTG16:E protein interactions partially phenocopied the enhanced tumorigenicity of Mtg16 –/– colon in the azoxymethane/DSS-induced model of CAC, indicating that MTG16 protects from tumorigenesis through additional mechanisms. Collectively, our results demonstrate that MTG16, via its repression of E protein targets, is a key regulator of cell fate decisions during colon homeostasis, colitis, and cancer.
- 23 May 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (10)
Open AccessMTG16 regulates colonic epithelial differentiation, colitis, and tumorigenesis by repressing E protein transcription factors
Aberrant epithelial differentiation and regeneration contribute to colon pathologies, including inflammatory bowel disease (IBD) and colitis-associated cancer (CAC). Myeloid translocation gene 16 (MTG16, also known as CBFA2T3) is a transcriptional corepressor expressed in the colonic epithelium. MTG16 deficiency in mice exacerbates colitis and increases tumor burden in CAC, though the underlying mechanisms remain unclear. Here, we identified MTG16 as a central mediator of epithelial differentiation, promoting goblet and restraining enteroendocrine cell development in homeostasis and enabling regeneration following dextran sulfate sodium–induced (DSS-induced) colitis. Transcriptomic analyses implicated increased Ephrussi box–binding transcription factor (E protein) activity in MTG16-deficient colon crypts. Using a mouse model with a point mutation that attenuates MTG16:E protein interactions ( Mtg16 P209T ), we showed that MTG16 exerts control over colonic epithelial differentiation and regeneration by repressing E protein–mediated transcription. Mimicking murine colitis, MTG16 expression was increased in biopsies from patients with active IBD compared with unaffected controls. Finally, uncoupling MTG16:E protein interactions partially phenocopied the enhanced tumorigenicity of Mtg16 –/– colon in the azoxymethane/DSS-induced model of CAC, indicating that MTG16 protects from tumorigenesis through additional mechanisms. Collectively, our results demonstrate that MTG16, via its repression of E protein targets, is a key regulator of cell fate decisions during colon homeostasis, colitis, and cancer.